| abstract |
Inhibitors of HCV of formula (I), and the N-oxides, salts, and stereoisomers thereof are disclosed, wherein the dashed line represents an optional double bond between atoms C7 and C8; R1 is hydrogen or C1-6alkyl; R2 is hydrogen or C1-6alkyl; and n is 3, 4, 5, or 6; pharmaceutical compositions containing compounds of formula (I) and processes for preparing compounds of formula (I) are provided. Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also disclosed. |